Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an ...

Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone announced the FDA issued a Complete Response Letter regarding its New ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...

Milestone Pharmaceuticals plans to request a Type A meeting with the FDA to address issues and move forward with the resubmission. China’s new tariffs just reignited the same market patterns ...

US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a ...

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its ...